Videx/Videx EC (didanosine): Labeling Revision – Risk of Non-Cirrhotic Portal Hypertension

by FDA on February 6, 2010

Risk information added to Warnings/Precautions section and data summary provided

This is a summary of an alert issued by MedWatch: The FDA Safety Information and Adverse Event Reporting Program. The link below will take you to the original notice.

View Full Details Of The Original MedWatch Notice Here.

Leave a Comment

Previous post: Cousins Products, Llc, Issues An Allergy Alert On Undeclared Egg, Soy, And Wheat In Spinach Vinaigrette

Next post: FDA Unveils Initiative to Reduce Unnecessary Radiation Exposure from Medical Imaging

_________________________

Canadian Recalls

Get All Of This Important Recall Information Sent Direct To Your Email Inbox. Our Weekly Newsletter Will Keep You Informed & Help Keep You And Your Family Safe.
First Name:
Primary Email:
Newsletter Options:


We hate spam as much as you do. We will never sell or share your email address with anyone.

Videx/Videx EC (didanosine): Labeling Revision – Risk of Non-Cirrhotic Portal Hypertension

Categories

Most Recent Recalls